Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: From structural findings to molecules

被引:56
作者
Cassoli J.S. [1 ]
Guest P.C. [1 ]
Malchow B. [2 ]
Schmitt A. [2 ,3 ]
Falkai P. [2 ]
Martins-De-Souza D. [1 ,3 ,4 ]
机构
[1] Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, University of Campinas (UNICAMP), Campinas
[2] Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich
[3] Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, University of São Paulo (USP), São Paulo
[4] UNICAMP's Neurobiology Center, Campinas
来源
npj Schizophrenia | / 1卷 / 1期
关键词
D O I
10.1038/npjschz.2015.34
中图分类号
学科分类号
摘要
Schizophrenia is a severe psychiatric disorder with multi-factorial characteristics. A number of findings have shown disrupted synaptic connectivity in schizophrenia patients and emerging evidence suggests that this results from dysfunctional oligodendrocytes, the cells responsible for myelinating axons in white matter to promote neuronal conduction. The exact cause of this is not known, although recent imaging and molecular profiling studies of schizophrenia patients have identified changes in white matter tracts connecting multiple brain regions with effects on protein signaling networks involved in the myelination process. Further understanding of oligodendrocyte dysfunction in schizophrenia could lead to identification of novel drug targets for this devastating disease.
引用
收藏
相关论文
共 159 条
  • [1] Jablensky A., Epidemiology of schizophrenia: The global burden of disease and disability, Eur Arch Psychiatry Clin Neurosci, 250, pp. 274-285, (2000)
  • [2] Hafner H., An Der Heiden W., Schizophrenia, pp. 101-141, (2007)
  • [3] International Statistical Classification of Diseases and Related Health Problems 10th Revision, (2010)
  • [4] Lambert M., Karow A., Leucht S., Schimmelmann B.G., Naber D., Remission in schizophrenia: Validity, frequency, predictors, and patients' perspective 5 years later, Dialogues Clin Neurosci, 12, pp. 393-407, (2010)
  • [5] Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Et al., World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, World J Biol Psychiatry, 13, pp. 318-378, (2012)
  • [6] Biological insights from 108 schizophrenia-associated genetic loci, Nature, 511, pp. 421-427, (2014)
  • [7] Schmitt A., Malchow B., Hasan A., Falkai P., The impact of environmental factors in severe psychiatric disorders, Front Neurosci, 8, (2014)
  • [8] Girard T.A., Christensen B.K., Rizvi S., Visual-spatial episodic memory in schizophrenia: A multiple systems framework, Neuropsychology, 24, pp. 368-378, (2010)
  • [9] Falkai P., Schmitt A., Cannon T.D., Pathophysiology of schizophrenia, Schizophrenia: Current Science and Clinical Practice, pp. 31-65, (2011)
  • [10] Hunter R., Barry S., Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment, Eur Psychiatry, 27, pp. 432-436, (2012)